Цефтибутен: место в терапии инфекций | КМАХ

Цефтибутен: место в терапии инфекций

Клиническая Микробиология и Антимикробная Химиотерапия. 2006; 8(4):368-382

​ Веселов А.В., Козлов Р.С.
цефалоспорины цефтибутен внебольничная пневмония синусит фарингит острый средний отит простатит
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2006; 8(4):368-382

Аннотация

Бета-лактамы остаются наиболее применяемыми антибиотиками во всём мире, среди которых цефалоспорины занимают одно из ведущих мест. Это обусловлено не только широким спектром действия, но и хорошей переносимостью антибиотиков данного класса. Пероральная терапия с использованием бета-лактамов является неотъемлемой составляющей лечения как амбулаторных больных, так и при ступенчатой терапии нозокомиальных инфекций. В данном обзоре дана клинико-фармакологическая характеристика перорального цефалоспорина III поколения цефтибутена и сделана попытка определить его место в современной терапии инфекций различной локализации.

  • 1. Kumazawa J., Yagisawa M. The history of antibiotics: The Japanese story. J Infect Chemother 2002; 8:125-33.
  • 2. Braga P.C., Piatti G. Kinetics of filamentation of Escherichia coli induced by different sub-MICs of ceftibuten at different times. Chemotherapy 1993; 39:272-7.
  • 3. Wise R., Andrews J.M., Ashby J.P., Thornber D. Ceftibuten: a new orally absorbed cephalosporin – in vitro activity against strains from the United Kingdom. Diagn. Microbiol. Infect Dis 1991; 14:45-52.
  • 4. Braga P.C., Piatti G., Dal Sasso M., et al. The in vitro effects of ceftibuten on the host defense mechanism. Chemotherapy 1994; 40:37-41.
  • 5. Bauernfeind A. Ceftibuten and bacterial kinetics: comparative in vitro activity against Enterobacteriaceae producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 1991; 14:89-92.
  • 6. Jones R.N., Barry A.L. Antimicrobial activity, spectrum and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SGH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother 1988; 32:1576-82.
  • 7. Craig W.A., Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15:255-9.
  • 8. Barry A.L., Jones R.N., and the Collaborative Antimicrobial Susceptibility Testing Group. Interpretive criteria and quality control limits for ceftibuten disc susceptibili ty tests. J Clin Microbiol 1990; 28:605-7.
  • 9. Shawar R., LaRocco M., Cleary T.G. Comparative in vitro acti­vity of ceftibuten (Sch 39720) against bacterial enteropathogens. Antimicrob Agents Chemother 1989; 33:781-4.
  • 10. Liao C.H., Sheng W.H., Wang J.T., et al. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect 2006; 39:59-66.
  • 11. Wiseman L.R., Balfour J.A. Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994; 47:784-808.
  • 12. Bragman S.G.L., Casewell M.W. The in vitro activity of ceftibuten against 475 clinical isolates of gram-negative bacilli, compared with cefuroxime and cefadroxil. J Antimicrob Chemother 1990; 25:221-6.
  • 13. Jones R.N. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiological features. Pediatr Infect Dis J 1995; 14(7 Suppl):S77-S83.
  • 14. Wise R., Andrews J.M., Ashby J.P., Thornber D. Ceftibuten – in vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action. J Antimicrob Chemother 1990; 26:209-13.
  • 15. Neu H.C. Ceftibuten: minimal inhibitory concentrations, post-antibiotic effect, beta-lactamase stability – a rationale for dosing programs. Pediatr Infect Dis J 1995; 14(7 Suppl):S88-92.
  • 16. Jones R.N., Barry A.L. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin. Chemioterapia 1988; 7:283-6.
  • 17. Jones R.N., Barry A.L., The Collaborative Antimicrobial Susceptibility Testing Group. Ceftibuten (7432-S; SGH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines. Eur J Clin Microbiol Infect Dis 1988; 7:802-7.
  • 18. Verbist L., Jacobs J., Hens K. Comparative antimicrobial activity of ceftibuten against multiply-resistant micro­organisms from Belgium. Diagn Microbiol Infect Dis 1991; 14:53-61.
  • 19. Debbia E.A., Schito G.C., Pesce A. Antibacterial activity of ceftibuten, a new oral third generation cephalosporin. J Chemother 1991; 3:209-55.
  • 20. Doern G.V. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarrhalis. Diagn Microbiol Infect Dis 1991; 14:75-7.
  • 21. Jones R.N. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiological features. Pediatr Infect Dis J 1995; 14(7 Suppl):S77-S83.
  • 22. Kitzis M.-D., Liassine N., Ferre В., et al. In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1990; 34:1783-6.
  • 23. Bedenic B., Vranes J., Suto S., Zagar Z. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases. Int J Antimicrob Agents 2005; 25:479-87.
  • 24. Guerillot F., Garret G., Flandrois J.P. A statistical evaluation of the bactericidal effects of ceftibuten in combination with aminoglycosides and ciprofloxacin. J Antimicrob Chemother 1993; 32:685-94.
  • 25. Barr W.H., Affrime M., Lin C.-C., Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1995; 14(7 Suppl):S93-101.
  • 26. Barr W.H., Lin C.C., Radwanski E., et al. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 1991; 14:93-100.
  • 27. Wise R., Nye K., O’Neill P., et al. Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother 1990; 34:1053-5.
  • 28. Scaglione F., Triscari F., Demartini G., et al. Concentrations of ceftibuten in bronchial secretions. Chemotherapy 1995; 41:229-33.
  • 29. Kelloway J.S., Awni W.M., Lin C.C., et al. Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency. Antimicrob Agents Chemother 1991; 35:2267-74.
  • 30. Kearns G.L., Reed M.D., Jacobs R.F., et al. Singledose pharmacokinetics of ceftibuten (SCH 39720) in infants and children. Antimicrob Agents Chemother 1991; 35:2078-84.
  • 31. Bachmann K., Schwartz J., Jauregui L., et al. Failure of ceftibuten to alter single-dose theophylline clearance. J Clin Pharmacol 1990; 30:444-8.
  • 32. Radwanski E., Nomeir A., Cutler D., et al. Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid Mylanta double-strength liquid or with ranitidine. Am J Ther 1998; 5:67-72.
  • 33. Reidenberg B.E. Worldwide safety experience with ceftibuten pediatric suspension. Pediatr Infect Dis J 1995; 14(7 Suppl):S130-3.
  • 34. Hashimoto H., Yamaguchi S., Yachiku S. Clinical studies of ceftibuten in the field of urology. Japan J Antibiotics 1990; 53:355-61.
  • 35. Muzutani S, Nishimura K., Yoshimura K., et al. Clinical experience with ceftibuten in complicated urinary tract infections. Japan J Antibiotics 1990; 53:779-89.
  • 36. Stein G.E., Christensen S., Mummaw N. Treatment of acute uncomplicated urinary tract infection with ceftibuten. Infection 1991; 19:124-6.
  • 37. Suzuki K., Nagata Y., Horiba M. Clinical studies on ceftibuten in the urinary field infection. Japan J Antibiotics 1990; 53:2003-10.
  • 38. Banfi A., Gabriele G., Hill-Juarez J.M., et al. Multinational comparative trial of ceftibuten and trimethoprim/ sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Pediatr Infect Dis J 1993; 12(Suppl.):S84-S91.
  • 39. Biemond A., de Fijter C.W.H., Oe P.L., et al. Oral treatment of complicated urinary tract infections: Ceftibuten (Sch39720) versus trimethoprim-sulfamethoxazole (TMP-SMX). Nether J Med 1991; 39:A43.
  • 40. Kumazawa J., Matsumoto T., Kumamoto Y., et al. A double-blind comparative study of ceftibuten and cefaclor for the treatment of complicated urinary tract infections. Nishinihon J Urology 1990; 52:921-37.
  • 41. Ho M.-W., Wang F.-D., Fung C.-P., Liu C.-Y. Comparative study of ceftibuten and cefixime in the treatment of complicated urinary tract infections. J Microbiol Immunol Infect 2001; 34:185-9.
  • 42. Inamatsu T., Fukayama M., Kato A., et al. Pharmacokinetics and clinical evaluation of 7432-S (a new oral cephem) in elderly patients. Chemotherapy 1989; 37(Suppl.):217-30.
  • 43. Takasugi M., Matsumoto K., Shishido H., et al. Basic and clinical studies on 7432-S, a new oral cephem. Chemotherapy 1989; 37(Suppl. 1):298-313.
  • 44. Watanabe A., Oizumi K., Motomiya M., et al. Therapeutic efficacy of ceftibuten in chronic respiratory tract infections. Japan J Antibiotics 1990; 43:768-78.
  • 45. McCabe R., Rumans L., Perrotta R., Magabgad W. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis. J Chemother 1993; 5:124-32.
  • 46. Nasu M., Saitoh A., Ohizumi K., et al. Comparative clinical study of 7432-S (ceftibuten) and cefaclor in chronic respiratory tract infections by a double-blind study. Chemotherapy 1989; (Suppl. A):A126.
  • 47. Blumer J.L., McLinn S.E., DeAbate C.A., et al. Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Pediatr Infect Dis J 1995; 14(7 Suppl.):S115-20.
  • 48. McLinn S.E., McCarty J.M., Perrotta R., et al. Multicenter controlled trial comparing ceftibuten with amoxicillin/ clavulanic acid in the empiric treatment of acute otitis media. Pediatr Infect Dis J 1993; 12(Suppl.):S70-S76.
  • 49. Pichichero M.E., McLinn S.E., Gooch W.M., et al. Ceftibuten vs. penicillin V in group A beta-hemolytic streptococcal pharyngitis. Pediatr Infect Dis J 1995; 14(7 Suppl):S102-7.
  • 50. De Abate C.A., Perrott R.J., Dennington M.L., et al. The efficacy and safety of once-daily ceftibuten compared with co-amoxiclav in the treatment of acute bacterial sinusitis. J Chemother 1993; 4:358-63.
  • 51. Guest N., Langan C.E. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Int J Antimicrob Agents 1998; 10:49-54.
  • 52. Adam D., Scholz H., Helmerking M. Five days ceftibuten versus 10 days penicillin in the treatment of 2099 patients with A-streptococcal tonsillopharyngitis. Fortschr Med Orig 2001; 119(Suppl 2):63-70.
  • 53. Bocazzi A., Tonelli P., Angelis M., et al. Short course therapy with ceftibuten versus azithromycin in pediatric streptococcal pharyngitis. Pediatr Infect Dis J 2000; 19:963-7.
  • 54. Drago L., Ripa S., Zampaloni C., et al. Activity of ceftibuten, cefaclor, azithromycin, clarithromycin, erythromycin and telithromycin against Streptococcus pyogenes clinical isolates with different genotypes and phenotypes. Chemotherapy 2005; 51:268-71.
  • 55. Sterkers O. Efficacy and tolerability of ceftibuten ver­sus amoxicillin/clavulanate in the treatment of acute sinusitis. Chemotherapy 1997; 43:352-7.
  • 56. Cho N., Fukunaga K., Kunii K., Kimura T. 7432-S in the obstetric and gynecological field. Chemotherapy 1989; 37(Suppl.):570-8.
  • 57. Yamamoto T., Yasuda J., Kanao M., Okada H. Basic and clinical studies on 7432-S in the field of obstetrics and gynecology. Chemotherapy 1989; 37(Suppl. 1):600-6.
  • 58. Matsuda S., Shimizu T., Maki M., et al. Comparative double-blind clinical trial of ceftibuten (7432-S) and bacampicillin (BAPC) against gynecological infections. Chemotherapy 1989; 37(Suppl. 1):667-700.
  • 59. Prado D., Lopez E., Liu H., et al. Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease. Pediatr Infect Dis J 1992; 11:644-7.
  • 60. Moolasart P., Eampokalap B., Ratanasrithong M. Comparison of the efficacy of ceftibuten and norfloxacin in the treatment of acute gastrointestinal infection in children. Southeast Asian J Trop Med Public Health 1999; 30:764-9.
  • 61. Dubey A. K., Vidyashankar C., Bhata S. S., Sharma R. K. Ceftibuten in enteric fever. Indian Pediatrics 2000; 37:222.
  • 62. Chong L.Y., Cheung W.M., Leung C.S., et al. Clinical evaluation of ceftibuten in gonorrhea. A pilot study in Hong Kong. Sex Transm Dis 1998; 25:464-7.
  • 63. Data available from www.cedax.com.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились